Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.64 |
| ▸ | SLC6A9 | P48067 | 4/20 | 0.44 |
| ▸ | GPR6 | P46095 | 8/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | FPR2 | P25090 | 1/20 | 0.40 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14634276 | 1.00 | GPR119 (0.64) | GPR119SLC6A9GPR6CYP2C9KCNH2 | |
| Hydrochloric Acid SCHEMBL2555358 | 0.85 | GPR119 (0.67) | GPR119SLC6A9GPR6CYP2C9KCNH2 | |
| Hydrochloric Acid SCHEMBL2555357 | 0.85 | GPR119 (0.67) | GPR119SLC6A9GPR6CYP2C9KCNH2 | |
| SCHEMBL14634462 | 0.82 | GPR119 (0.76) | GPR119SLC6A9GPR6CYP2C9 | |
| SCHEMBL14634465 | 0.82 | GPR119 (0.76) | GPR119SLC6A9GPR6CYP2C9 | |
| SCHEMBL14634424 | 0.81 | GPR119 (0.60) | GPR119 | |
| SCHEMBL14634426 | 0.81 | GPR119 (0.60) | GPR119 | |
| Hydrochloric Acid SCHEMBL14634645 | 0.79 | GPR119 (0.60) | GPR119SLC6A9GPR6CYP2C9FPR2 | |
| Hydrochloric Acid SCHEMBL14634644 | 0.79 | GPR119 (0.60) | GPR119SLC6A9GPR6CYP2C9FPR2 | |
| SCHEMBL16010853 | 0.78 | GPR119 (0.43) | GPR119SLC6A9GPR6CYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130023494-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. (US) | 2013-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023494-A1 | MODULATORS OF THE GPR119 RECEPTOR AND THE TREATMENT OF DISORDERS RELATED THERETO | GPR119, SLC5A2, SLC5A1 | GPR119 1/4885SLC6A9 99/4885GPR6 37/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.